AUG 20, 2018 8:35 AM PDT

Drug Seeks To Prevent a Painful Side-Effect

WRITTEN BY: Nouran Amin

Many patients with head, neck, nasal, and oral cancers are treated with radiations. Unfortunately, such treatment leaves patients with a painful side-effect known as severe oral mucositis (SOM). Even though there are drugs on the market that treat SOM, there isn’t yet anything effective to prevent it.

Now, researchers at the 256th National Meeting & Exposition of the American Chemical Society (ACS) have reported on a new drug referred to as ‘GC4419’ which may actually prevent SOM. Despite still being investigated in clinical trials, it is labeled as a “breakthrough therapy” by the U.S Food and Drug Administration. "It is exciting to publicly report on the structure and synthesis of GC4419 for the first time," says Dennis P. Riley, Ph.D., leader of the study. "We believe GC4419 has the potential to address an important unmet medical need in the treatment of cancer patients undergoing radiation therapy, and we look forward to commencing a Phase 3 trial with GC4419 in head and neck cancer patients this year."

 

Watch video below for a background overview on SOM:

 

Radiation therapy breaks down the epithelial lining on the insides of the mouth due to highly elevated superoxide radical levels which eventually causes the painful oral mucositis (OM) "The synthetic enzyme we designed and made mimics the function of the naturally occurring superoxide dismutase, an enzyme that converts superoxide to molecular oxygen and hydrogen peroxide," expalains Riley, who is with Galera Therapeutics. "Hydrogen peroxide is very toxic to cancer cells but not to normal cells. Thus, we create two opportunities to improve radiation therapy: reducing toxicity for normal cells while increasing the toxicity to the cancerous ones."

The research team faced many challenges in designing and creating a synthetic superoxide dismutase due to the complex molecular composition. "We had to figure out which isomer would work best and be the most 'druggable,'" reports Riley. "Our current synthesis involves using a template to make the 15-membered macrocylic ring complex in a single GMP [Good Manufacturing Practice] step. It uses pyridine-2,6- dicarboxyaldehyde, manganese(II) chloride and a linear tetramine synthesized from S,S-1,2 diaminocyclohexane. It is an elegantly simple 'one-pot' synthesis that yields the desired molecule with more than 99.5 percent chemical purity."

GC4419 has gone through successful completion of the Phase 1 and 2 clinical trials, which proved the safety and efficacy for SOM prevention in patients with head and neck cancer undergoing radiation therapy. Upon successful completions of the remaining phases in the trial, GC4418 will receive FDA approval.

Source: Science Daily

About the Author
BS/MS
Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
MAY 19, 2022
Drug Discovery & Development
Experimental Drug Shows Promise Against ALS
MAY 19, 2022
Experimental Drug Shows Promise Against ALS
A new experimental drug known as NU-9 may be more effective in treating ALS than existing FDA-approved drugs. The corres ...
JUN 09, 2022
Plants & Animals
Traditional Indian Medicine Helps Treat and Manage Type 2 Diabetes
JUN 09, 2022
Traditional Indian Medicine Helps Treat and Manage Type 2 Diabetes
Medicine has been practiced for millennia. Despite the dominance of Western medicine, many traditional approaches to tre ...
JUN 09, 2022
Cancer
A Case Study May Identify a Novel Gene Therapy for Pancreatic Cancer
JUN 09, 2022
A Case Study May Identify a Novel Gene Therapy for Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive pancreatic cancer with limited treatment options.  PDA ...
JUN 13, 2022
Cancer
Clinical Trial Demonstrates an Amazing 100% Response
JUN 13, 2022
Clinical Trial Demonstrates an Amazing 100% Response
The results of a Clinical Trial for rectal cancer patients published last week in the New England Journal of Medicine co ...
JUN 15, 2022
Drug Discovery & Development
High Intensity Ultrasound Therapy Treats Localized Prostate Cancer
JUN 15, 2022
High Intensity Ultrasound Therapy Treats Localized Prostate Cancer
High-intensity-focused ultrasound (HIFU) can treat some men with prostate cancer instead of surgery or radiation therapy ...
JUN 27, 2022
Drug Discovery & Development
Potential Gene Targets Identified for Treating Deafness
JUN 27, 2022
Potential Gene Targets Identified for Treating Deafness
Researchers have identified three mutations of the MINAR2 gene that are linked to deafness. They say that the mutations ...
Loading Comments...